FATEFate Therapeutics, Inc.

$143M

FY 2015 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M

Gross Profit

-$17M-717.0% margin

Operating Income

-$28M-1142.8% margin

Net Income

-$30M-1233.7% margin

EPS (Diluted)

$-1.18

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$20M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$68M

Total Liabilities

$30M

Stockholders' Equity

$38M

Cash & Equivalents

$65M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$0	—
Gross Profit	-$17M	-$16M	-6.1%
Operating Income	-$28M	-$25M	-11.6%
Net Income	-$30M	-$26M	-15.9%

FATE FY 2015 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena